|
|
Background: The aim of our study was to evaluate the possible determination of everolimus concentrations using the newly-introduced sirolimus antibody conjugated magnetic immunoassay (ACMIA).
Methods: Everolimus concentrations were determined in 100 blood samples from kidney (n = 47) and liver (n = 53) transplant recipients using the IMx® sirolimus microparticle enzyme immunoassay (MEIA) from Abbott as previously described (Clin Biochem 2007;40:132-36) and sirolimus ACMIA from Siemens Healthcare Diagnostics Ltd.
Results: The ACMIA everolimus values were significantly higher than those of MEIA (p < 0.001). Analogous slope and intercept values were obtained in the linear regression between the ACMIA and MEIA results when compared to the Seradyn® Certican® everolimus controls or the blood samples from transplant recipients. Correction of the ACMIA values using the regression equation obtained for the control material (ACMIAcorrected = 0.55 ACMIA + 1.14) led to a satisfactory relationship with the results provided by the MEIA for the patients’ samples (MEIA = 1.00 ACMIAcorrected + 0.30, r = 0.905, p < 0.001).
Conclusions: The sirolimus ACMIA on the Dimension® platform, which does not require manual pre-treatment of the blood samples, may be an acceptable option for therapeutic everolimus monitoring, significantly reducing technician time in comparison to other widely-used immunoassays.
DOI: Clin. Lab. 2011;57:403-406
|
